Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety, tolerability, and pharmacokinetics of OMS643762 in psychiatrically stable schizophrenia subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• OMS643762

Snippet

Sponsor: Omeros Corporation | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED